PortfoliosLab logoPortfoliosLab logo
ISIN
US22529Y3099
IPO Date
Nov 6, 2015

Highlights

Market Cap
$1.71M
Enterprise Value
-$4.01M
EPS (TTM)
-$1.99
Total Revenue (TTM)
$3.00K
Gross Profit (TTM)
-$59.69K
EBITDA (TTM)
-$4.39M
Year Range
$0.66 - $6.25
ROA (TTM)
-89.46%
ROE (TTM)
-94.31%
Avg. Volume (1M)
391K
Avg. Volume Value (1M)
$394.24K

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Often compared with CELZ:
CELZ vs. GAIN

Performance

CELZ Performance Chart

Creative Medical Technology Holdings Inc (CELZ) is down 66.1% since the beginning of the year. At $1 per share, CELZ is trading 89.4% below its 52-week high of $6. Investors who bought $1,000 worth of CELZ shares 5 years ago would now be looking at an investment worth $5.


Loading charts...

Benchmark

Compare this symbol against anything

Returns By Period

Creative Medical Technology Holdings Inc (CELZ) has returned -66.12% so far this year and -76.86% over the past 12 months. Over the last ten years, CELZ has returned -73.46% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.


Creative Medical Technology Holdings Inc

1D
-13.12%
1M
-45.12%
6M
-67.13%
YTD
-66.12%
1Y
-76.86%
3Y*
-50.81%
5Y*
-65.53%
10Y*
-73.46%
ALL TIME*
-58.46%

Benchmark (S&P 500 Index)

1D
0.70%
1M
0.09%
6M
7.94%
YTD
9.41%
1Y
20.07%
3Y*
17.84%
5Y*
11.25%
10Y*
13.26%
ALL TIME*
8.09%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CELZ Monthly Returns History

Based on dividend-adjusted daily data since Nov 6, 2015, CELZ's average daily return is +2.12%, while the average monthly return is +42.82%. At this rate, an investment would double in approximately 0.2 years.

Historically, 27% of months were positive and 73% were negative. The best month was Apr 2016 with a return of +4,445.5%, while the worst month was Nov 2017 at -77.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CELZ closed higher 34% of trading days. The best single day was Apr 28, 2016 with a return of +4,445.5%, while the worst single day was May 18, 2016 at -80.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20263.06%-10.40%13.81%9.22%-0.00%-35.56%-54.21%-66.12%
202535.50%58.79%-56.34%-4.61%5.31%21.56%4.91%14.39%4.72%-4.80%-15.14%-27.14%-15.15%
2024-8.24%-1.65%25.24%-14.78%-2.03%-11.49%-9.87%0.29%-10.92%33.55%-35.63%-13.32%-49.89%
202340.38%6.54%-12.28%29.68%-12.08%-18.70%18.88%-13.98%3.80%-10.77%1.37%3.60%20.97%
2022-7.24%-11.22%114.29%-51.79%-51.01%-18.57%-1.33%-5.68%-36.96%-2.27%-4.67%-7.03%-82.76%
2021-10.07%88.00%-29.47%32.73%-18.18%-2.78%-22.00%-0.37%-44.85%-3.33%-40.69%-48.60%-84.10%

Benchmark Metrics

Creative Medical Technology Holdings Inc has an annualized alpha of 22772.04%, beta of -1.04, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since November 06, 2015.

  • This stock participated in 254.51% of S&P 500 Index downside but only -24.51% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of -1.04 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
22,772.04%
Beta
-1.04
0.00
Upside Capture
-24.51%
Downside Capture
254.51%

Return for Risk

Risk / Return Rank

CELZ ranks 13 for risk / return — above 13% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.


CELZ Risk / Return Rank: 1313
Overall Rank
CELZ Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
CELZ Sortino Ratio Rank: 1515
Sortino Ratio Rank
CELZ Omega Ratio Rank: 1313
Omega Ratio Rank
CELZ Calmar Ratio Rank: 99
Calmar Ratio Rank
CELZ Martin Ratio Rank: 99
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

Risk / Return Metrics

The table below present risk-adjusted performance metrics for Creative Medical Technology Holdings Inc (CELZ) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CELZBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-2.02

Sortino ratioReturn per unit of downside risk

-2.80

Omega ratioGain probability vs. loss probability

0.88

1.25

-0.37

Calmar ratioReturn relative to maximum drawdown

-0.87

2.00

-2.87

Martin ratioReturn relative to average drawdown

-1.36

8.49

-9.85

Dividends

Dividend History


Creative Medical Technology Holdings Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Creative Medical Technology Holdings Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Creative Medical Technology Holdings Inc was 100.00%, occurring on Jul 31, 2026. The portfolio has not yet recovered.

The current Creative Medical Technology Holdings Inc drawdown is 100.00%.


Drawdown

Fall

Recovery

Underwater

Related event

-100.00%Jul 2026
10y 1mo
10y 1moJun 2016 - now
-80.00%May 2016
1d20d
20dMay 2016 - Jun 2016

Drawdown Indicators


CELZBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-56.78%

-43.22%

Max Drawdown (1Y)

Largest decline over 1 year

-88.12%

-9.10%

-79.02%

Max Drawdown (3Y)

Largest decline over 3 years

-89.71%

-18.90%

-70.81%

Max Drawdown (5Y)

Largest decline over 5 years

-99.62%

-25.43%

-74.19%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

-33.92%

-66.08%

Current Drawdown

Current decline from peak

-100.00%

-1.58%

-98.42%

Average Drawdown

Average peak-to-trough decline

-85.86%

-10.70%

-75.16%

Ulcer Index

Depth and duration of drawdowns from previous peaks

55.90%

2.14%

+53.76%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Creative Medical Technology Holdings Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Creative Medical Technology Holdings Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CELZ relative to other companies in the Biotechnology industry. Currently, CELZ has a P/S ratio of 639.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for CELZ in comparison with other companies in the Biotechnology industry. Currently, CELZ has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with CELZ

Add Creative Medical Technology Holdings Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with CELZ